A spectrum or intermediate paradigm is emerging which encompasses this variable capacity to form distant metastatic disease, with more indolent, slower growing tumours (luminal subtypes) behaving according to the Halstedian paradigm and more aggressive tumours (triple negative and HER2 positive cancers) disseminating early on – consistent with the Fisherian paradigm (25). Here, ERBB2 is linked to neoplasm.